Mark Elliott Boulding - 20 Sep 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role: EXEC. VP AND CLO
Signature: /s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol: PTCT
Transactions as of: 20 Sep 2022
Net transactions value: -$64,680
Form type: 4
Filing time: 22 Sep 2022, 16:38:13 UTC
Previous filing: 15 Apr 2022
Next filing: 19 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTCT	Common Stock	Options Exercise	$27,033	+876	+1.4%	$30.86	61,986	20 Sep 2022	Direct	F1
transaction	PTCT	Common Stock	Sale	$48,180	-876	-1.4%	$55.00	61,110	20 Sep 2022	Direct	F1
transaction	PTCT	Common Stock	Options Exercise	$9,258	+300	+0.49%	$30.86	61,410	20 Sep 2022	Direct	F1
transaction	PTCT	Common Stock	Sale	$16,500	-300	-0.49%	$55.00	61,110	20 Sep 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTCT	Stock Option (Right to Buy)	Options Exercise	$27,033	-876	-1.3%	$30.86	69,124	20 Sep 2022	Common Stock	70,000	$30.86	Direct	F2
transaction	PTCT	Stock Option (Right to Buy)	Options Exercise	$9,258	-300	-0.43%	$30.86	68,824	20 Sep 2022	Common Stock	69,124	$30.86	Direct	F2
holding	PTCT	Stock Option (Right to Buy)						85,600	20 Sep 2022	Common Stock	85,600	$51.00	Direct	F2
holding	PTCT	Stock Option (Right to Buy)						72,500	20 Sep 2022	Common Stock	72,500	$33.02	Direct	F3
holding	PTCT	Stock Option (Right to Buy)						17,500	20 Sep 2022	Common Stock	17,500	$33.02	Direct	F4
holding	PTCT	Stock Option (Right to Buy)						59,500	20 Sep 2022	Common Stock	59,500	$51.16	Direct	F5
holding	PTCT	Stock Option (Right to Buy)						59,500	20 Sep 2022	Common Stock	59,500	$66.49	Direct	F6
holding	PTCT	Stock Option (Right to Buy)						54,000	20 Sep 2022	Common Stock	54,000	$38.10	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021.
F2	Currently exercisable.
F3	This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F4	This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F5	This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F6	This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
F7	This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.